Entrada Therapeutics, Inc.
TRDANASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $186.20M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $4.11$16.45
- Volume (live)
- -
- Avg. volume (3M)
- 351.91K
Entrada Therapeutics (TRDA) Stock Price & Financial Analysis
Entrada Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $4.39 - $4.70 |
|---|---|
| 52-Week High | $16.45 |
| 52-Week Low | $4.11 |
| Open | $4.67 |
| Volume (last close) | 191.47K |
| Average Volume (3M) | 351.91K |
| Revenue (TTM) | 4.69M |
|---|---|
| Net Income (TTM) | -165.78M |
| Free Cash Flow (TTM) | -135.00M |
| EPS (TTM) | −$3.97 |
| Profit Margin | -3537.73% |
| Operating Margin | -3767.07% |
| Return on Equity (ROE) | -71.02% |
| Debt to Equity | 0.21 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 186.20M |
|---|---|
| Shares Outstanding | 42.22M |
| Price to Sales (P/S) | 39.73 |
| Price to Book (P/B) | 0.80 |
| EV/EBITDA | -0.88 |
| 50-Day MA | $6.50 |
|---|---|
| 200-Day MA | $9.00 |
| 1-Year Change | −26.09% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Entrada Therapeutics at a Glance
As of the Oct 23, 2026 close, Entrada Therapeutics (TRDA) has a market capitalization of $186.20M. The stock trades at 39.7× sales. Over the trailing twelve months it lost $165.78M on revenue of $4.69M and burned $135.00M of free cash flow. Revenue fell 94.1% year over year.
As of its latest reported balance sheet, it holds $99.28M in cash and securities against $48.54M of debt, a net cash position of $50.74M.
Entrada Therapeutics does not currently pay a dividend.
The share price is down 26.1% over the past year. At $4.41 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $4.11 to $16.45, below its 200-day moving average of $9.00.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $19.67, 346.0% above the Oct 23, 2026 close.
Frequently Asked Questions About Entrada Therapeutics
What is the current stock price for TRDA?
As of the Oct 23, 2026 close, TRDA stock trades at $4.41. The 52-week range is $4.11–$16.45, with a day range of $4.38–$4.70.
What is the P/E ratio for TRDA?
The P/E ratio (Price-to-Earnings) for TRDA is shown in the Key Statistics section. This valuation metric helps compare Entrada Therapeutics, Inc. to industry peers.
Does TRDA pay dividends?
Entrada Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for TRDA?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for TRDA is Buy. The average 12-month price target is $19.67, a 346.0% upside from the Oct 23, 2026 close of $4.41.
What is the market cap of TRDA?
As of the Oct 23, 2026 close, Entrada Therapeutics's market capitalization is $186.2M, classifying it as a micro-cap company. Entrada Therapeutics operates in the Healthcare sector within the Biotechnology industry.